BPC-157 Dosage: What Animal Research Suggests in 2026

---

BPC-157 has one of the more robust preclinical research bases of any research peptide — spanning tendon repair, gastrointestinal healing, muscle recovery, and anti-inflammatory effects across hundreds of animal studies. But translating animal model doses to a research context is not straightforward, and the dosing question is where many researchers get stuck.

This guide summarizes the doses used in published BPC-157 animal research, the routes studied, and how researchers typically frame these findings. Nothing here is medical advice. BPC-157 is not FDA-approved and is sold for research purposes only.

---

What Doses Appear in the BPC-157 Research Literature?

The majority of published BPC-157 studies use rodent models (rats and mice). Doses in these studies typically fall in the range of 2–10 mcg/kg body weight administered once or twice daily, with some studies using doses up to 100 mcg/kg for specific tissue injury applications.

Subcutaneous Administration

Subcutaneous injection is the most commonly studied route for systemic applications including tendon repair, muscle healing, and anti-inflammatory effects. Most studies fall in the 2–10 mcg/kg range once daily. A 250g rat receiving 10 mcg/kg would receive approximately 2.5 mcg per injection — a very small amount.

Scaling animal doses to humans using body surface area (BSA) conversion (the FDA's standard approach for first-in-human estimates) produces estimates in the 200–500 mcg per administration range for a 70kg human, using a standard 6.2× BSA adjustment from rat data. These are rough estimates — not recommended doses.

Intraperitoneal Administration

Many studies administer BPC-157 intraperitoneally (IP injection into the abdominal cavity). IP dosing in rats typically uses similar mcg/kg ranges to subcutaneous, and researchers often treat IP and subcutaneous administration as roughly equivalent for systemic exposure.

Oral Administration

BPC-157 is unusual among peptides in being stable in gastric acid, which makes oral administration viable — particularly for gastrointestinal applications. Several studies have demonstrated efficacy via oral administration in colitis, ulcer, and gut permeability models. Oral doses in these studies tend to be higher — often 10–100 mcg/kg — reflecting reduced bioavailability via the oral route compared to injection.

Topical Application

Some research has studied BPC-157 in topical formulations for wound healing. This is a more niche research area with fewer published studies, and topical dosing is highly dependent on the formulation vehicle.

---

Cycle Length in Published Studies

Most BPC-157 studies run for 4–12 weeks, with shorter cycles (2–4 weeks) for acute injury models and longer cycles for chronic models of inflammation or degeneration. Daily administration is standard in nearly all published research.

---

Route Comparison at a Glance

Route	Typical Study Range	Common Applications
Subcutaneous	2–10 mcg/kg/day	Tendon, muscle, systemic
Intraperitoneal	2–10 mcg/kg/day	Most acute injury models
Oral	10–100 mcg/kg/day	GI-focused research
Topical	Variable	Wound healing models

---

The Human Translation Problem

A critical point: nearly all BPC-157 research is preclinical. There are no published Phase 1 or Phase 2 human clinical trials establishing safe or effective human doses. Any human-equivalent dose estimate is extrapolation from animal data — useful as a research starting point but not validated in humans.

The widely cited "200–500 mcg" figure that circulates in research communities comes from BSA-adjusted translation of rat doses, not from human trial data. Researchers should treat this as a rough order-of-magnitude estimate, not a precise therapeutic window.

---

Purity and Source Matter for Dosing Accuracy

Because BPC-157 is sold as a lyophilized powder requiring reconstitution, the actual delivered dose depends heavily on:

1. Peptide purity — lower purity means the actual BPC-157 content per mg is lower than labeled
2. Reconstitution accuracy — errors in bacteriostatic water volume directly affect concentration
3. Storage integrity — improperly stored peptides degrade and lose potency

A Certificate of Analysis (COA) from a third-party lab confirms purity. Suppliers without third-party COAs introduce an unknown variable into any dosing calculation. See our COA guide for how to verify documentation.

---

Current BPC-157 Pricing

Price varies significantly across suppliers. Compare prices per mg across 40+ suppliers using our live price tracker — purity-verified suppliers with third-party COAs are flagged.

---

Key Takeaways

• Published animal research uses 2–10 mcg/kg/day subcutaneously in most studies
• BSA-adjusted human estimates fall in the 200–500 mcg range — these are extrapolations, not clinical doses
• Oral administration has been studied (GI applications) but requires higher doses than injection
• No published human clinical trials define safe or effective human doses
• Purity and reconstitution accuracy directly affect delivered dose — source from COA-verified suppliers